Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

34.19 +1.05 (+3.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
3 Monster Stocks in the Making to Buy Right Now
They're small now, but these stocks could grow much larger. 
Via The Motley Fool
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. 
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
Blue Chips, Small Caps Extending Their Breakout
The Dow Jones Industrial Average is stealing the show today, last seen up 546 points for a new record high and on track for its best single-session gain since January 2023. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
CRISPR Therapeutics could start reporting product revenue soon. 
Via The Motley Fool
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
There are a handful of different factors that could buoy its stock. 
Via The Motley Fool
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
These two stocks could have vastly different long-term performances. 
Via The Motley Fool
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF, despite its recent underperformance. 
Via Benzinga
Topics ETFs
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
Via MarketBeat
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
7 Growth Stocks to Invest $500 In and Cash Out $100K by 2030
Investing $500 in these seven high-growth stocks could potentially turn into $100,000 by 2030, offering massive upside. 
Via InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
3 Pharma Stocks Already Ushering in the Next Biotech Boom
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider. 
Via InvestorPlace
3 Top-Rated Gene Editing Stocks Actually Making Money
Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond. 
Via InvestorPlace
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. 
Via InvestorPlace
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
These three biotech stocks to buy carry risks but may appeal to speculative investors with time and patience. 
Via InvestorPlace
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Invest in the top biotech stocks to buy, as the sector pivots from pandemic-driven vaccine sales to solutions for chronic conditions. 
Via InvestorPlace
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon. 
Via The Motley Fool
3 Biotech Stocks That Could Make Your Grandchildren Rich
These biotech stocks are poised to generate significant returns to investors due to their high growth potential. 
Via InvestorPlace
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks. 
Via InvestorPlace
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions. 
Via InvestorPlace
The Next Big Thing After AI? 3 Sleeper Stocks to Buy Before the Boom
These three sleeper stocks could deliver massive gains if their cutting-edge technologies take off in the coming years. 
Via InvestorPlace
7 ‘FIRE’ Stocks to Put You on the Path to Financial Freedom
With so many young people eager to get out of the corporate rat race, these FIRE stocks can accelerate your path and stay free. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
In keeping with Cathie Wood's style, these picks are riskier than average. 
Via The Motley Fool
Cathie Wood Has Been Steadily Selling Shares of This Growth Stock. Should You?
Teladoc's share performance has reflected its earnings struggles... 
Via The Motley Fool
7 Stocks You Haven’t Heard of (That EVERYONE Should Own)
These under-the-radar must-own stocks across various sectors are using powerful megatrends and posting solid financial results. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.